BUZZ-BioCryst 采取法律行动捍卫罕见基因药物专利;股价下跌

路透中文
11 Mar

3月11日 - ** 制药商 BioCryst Pharmaceuticals BCRX.O 股价下跌 2%,至 7.24 美元

** 根据美国证券交易委员会的文件,BCRX周一对Annora Pharma等公司提起 (link) 专利侵权诉讼。

** BCRX正在寻求阻止这些公司生产其罕见基因药物Orladeyo的仿制药,并推迟美国FDA的审批,直到专利到期。

** Annora声称,将于2039年到期的三项专利是无效的、不可执行的和/或不会被其仿制药侵犯。

** Annora 没有立即回应路透的置评请求

** BCRX 在 2024 年的涨幅约为 24

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."